Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.

Abstract

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.

• Authors: Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
• Journal: Clinical and molecular hepatology (Clin Mol Hepatol) Vol. 27 Issue 3 Pg. 402-412 (Jul 2021) ISSN: 2287-285X [Electronic] Korea (South)
• PMID: 34157830 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents
• entecavir
• Guanine
• Tenofovir

Topics

• Antiviral Agents (therapeutic use)
• Carcinoma, Hepatocellular (drug therapy, prevention & control)
• Cohort Studies
• Guanine (analogs & derivatives, therapeutic use)
• Hepatitis B virus (genetics)
• Hepatitis B, Chronic (complications, drug therapy)
• Humans
• Liver Neoplasms (drug therapy, prevention & control)
• Tenofovir (therapeutic use)
• Treatment Outcome